No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MD240719C7500
- 0.11
- 0.000.00%
15min DelayClose Jul 19 11:01 ET
0.11High0.11Low
0.11Open0.11Pre Close1 Volume1 Open Interest7.50Strike Price0.00Turnover332.16%IV-0.52%PremiumJul 19, 2024Expiry Date0.15Intrinsic Value100Multiplier-3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.5386Delta1.5871Gamma69.55Leverage Ratio-1.3927Theta0.0000Rho37.45Eff Leverage0.0003Vega
Intraday
- 5D
- Daily
News
Even After Rising 13% This Past Week, Pediatrix Medical Group (NYSE:MD) Shareholders Are Still Down 74% Over the Past Three Years
Pediatrix Medical Group, Inc. (NYSE:MD) shareholders should be happy to see the share price up 13% in the last week. But that doesn't change the fact that the returns over the last three years
Pediatrix Medical Group Up Over 7%, on Pace for Largest Percent Increase Since February 2023 -- Data Talk
Pediatrix Medical Group, Inc. (MD) is currently at $7.52, up $0.52 or 7.43% --Would be highest close since June 28, 2024, when it closed at $7.55 --On pace for largest percent increase since Feb. 17,
Truist Securities Cuts Price Target on Pediatrix Medical to $8 From $10, Maintains Hold Rating
Pediatrix Medical (MD) has an average hold rating and a price target range of $7.50 to $10, according to analysts polled by Capital IQ.Price: 7.23, Change: -0.17, Percent Change: -2.30
Pediatrix Medical Price Target Cut to $8.00/Share From $10.00 by Truist Securities
Pediatrix Medical Price Target Cut to $8.00/Share From $10.00 by Truist
Truist Securities Maintains Hold on Pediatrix Medical Group, Lowers Price Target to $8
Truist Securities analyst David Macdonald maintains Pediatrix Medical Group (NYSE:MD) with a Hold and lowers the price target from $10 to $8.
Truist Financial Maintains Pediatrix Medical(MD.US) With Hold Rating, Announces Target Price $8
Truist Financial analyst David S Macdonald maintains $Pediatrix Medical(MD.US)$ with a hold rating, and sets the target price at $8.According to TipRanks data, the analyst has a success rate of 63.2%
Comments
The recent insider selling at Pediatrix Medical Group, combined with the relatively low insider ownership, raises caution. The lack of insider buying over the past year also adds to this caution. The company is not considered a rush to buy.
Pediatrix Medical Group Insiders Sold US$957k Of Shares Suggesting Hesitancy 2
Pediatrix Medical Group's low P/E ratio may be due to expectations of falling earnings. The outlook for shrinking earnings contributes to its low P/E, acting as a barrier for the share price unless conditions improve.
1
The insider transactions at Pediatrix Medical Group lack confidence. The level of insider ownership is also not notably high. Potential investors should be aware of the associated risks.
Pediatrix Medical Group's ROCE trend reflects low reinvestment and stagnant returns, possibly contributing to a steep stock price drop. Better investments might be elsewhere.
The unchanged market sentiment towards Pediatrix Medical Group over the past year may suggest persistent challenges. Coupled with an annualized loss surpassing 11% in half a decade, it may not be a promising stock to buy.
Read more